Sienna has bigger value drivers than SNA-001 in acne, says BMO Capital

BMO Capital analyst Gary Nachman called Sienna Biopharmaceuticals’ announcement that SNA-001 failed in two of its three pivotal studies in acne an “unfortunate outcome,” but he believes the bigger long-term value drivers for Sienna remain SNA-001 for light-hair removal and SNA-125 for psoriasis and atopic dermatitis. After removing any SNA-001 acne revenue from his estimates, Nachman lowered his price target on Sienna Biopharmaceuticals to $27 from $30 and keeps an Outperform rating on the shares

https://bit.ly/2LQS83O